Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSCG | ISIN: US00510M1045 | Ticker-Symbol: 3ZO
Tradegate
21.11.24
16:02 Uhr
1,260 Euro
-0,050
-3,82 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACURX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ACURX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2461,28217:36
1,2461,28017:33

Aktuelle News zur ACURX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAcurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook21
MiACXP stock touches 52-week low at $1.5 amid market challenges1
MiACXP-Aktie erreicht 52-Wochen-Tief bei 1,5 US-Dollar2
MiAcurx Board of Directors Approves Bitcoin as Treasury Reserve Asset5
MiAcurx Pharmaceuticals investiert 1 Million US-Dollar in Bitcoin-Reserve4
MiAcurx Pharmaceuticals allocates $1M for Bitcoin reserve3
ACURX PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiAcurx Pharmaceuticals, Inc.: Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset162STATEN ISLAND, N.Y., Nov. 20, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class...
► Artikel lesen
13.11.Acurx Pharmaceuticals GAAP EPS of -$0.173
13.11.Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update67STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical...
► Artikel lesen
13.11.Acurx Pharmaceuticals, Inc. - 8-K, Current Report-
31.10.New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable Green Team, and SEKUR's "Hack of the Week"258The episode, airing at 9:30 PM PST, will include insights from The Sustainable Green Team with CEO Tony Raynor and Jimmy Houston.NEW YORK, NY / ACCESSWIRE / October 31, 2024 / New to The Street, a premier...
► Artikel lesen
28.10.New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical , Acurx Pharmaceuticals , and LightPath Technologies200Also appearing on the show are, Sustainable Green Team (OTCQX:SGTM), Andie Monet with David Fagen, and SEKUR (OTCQX:SWISF)NEW YORK, NY / ACCESSWIRE / October 28, 2024 / New to The Street on Fox Business...
► Artikel lesen
21.10.Acurx reports positive Phase 2 results for CDI treatment ibezapolstat1
21.10.Acurx Pharmaceuticals, Inc.: Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference68The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI) Ibezapolstat treatment...
► Artikel lesen
14.10.New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support308The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign.NEW YORK, NY / ACCESSWIRE / October 14, 2024 / New to The...
► Artikel lesen
26.09.Acurx berichtet über positive Mikrobiomeffekte und Anthrax-Aktivität von Ibezapolstat1
26.09.Acurx reports ibezapolstat's positive microbiome effects and Anthrax activity1
26.09.Acurx Pharmaceuticals, Inc.: Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues58New analyses extend data on beneficial effects of ibezapolstat on the gut microbiome Confirmed ibezapolstat's favorable pharmacokinetics showing low systemic exposure and high colonic concentrations Selected...
► Artikel lesen
24.09.Acurx readies ibezapolstat for Phase 3 CDI trials2
24.09.Acurx bereitet Ibezapolstat für Phase-3-Studien bei CDI vor1
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1